lipolysis is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-23. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
The Assam Legislative Assembly is the unicameral legislature of the Indian state of Assam. The Legislative Assembly comprises 126 Members of Legislative Assembly, directly elected from single-seat constituencies. Its term is five years, unless sooner dissolved. Members of the Assembly are directly elected by the people of Assam through elections held every five years, unless the Assembly is dissolved earlier. The current Assembly was elected in April–May 2026, and the next election is scheduled for 2031. The Assembly plays a key role in law-making for the state, handling crucial matters such as state budgets, development policies, and local governance. It has the authority to legislate on issues specified under the State and Concurrent Lists of the Constitution of India. The Assembly functions through various committees that handle specific issues, including the budget, public accounts, and legislative procedures. The Chief Minister, who is the leader of the majority party in the Assembly, holds executive powers and is the head of the state government.
=== Fifth Republic === December 23, 1958: Decree amending various criminal provisions to introduce a fifth class of police contraventions; notably punishes passive soliciting. December 30, 1958: The term "birth allowance" replaces "maternity allowance," and the conditions for both that and the single wage allowance are modified. February 4, 1959: Ordinance on the general status of civil servants, which includes the principle of non-discrimination based on sex, except in certain exceptional cases, notably in the national police. April 9, 1960: Decree concerning the family record book. November 25, 1960: Ordinance on the fight against pimping. November 25, 1960: By decree, passive soliciting becomes a 3rd-class offense, active soliciting a 5th-class offense. December 2, 1960: France ratifies the United Nations Convention for the Suppression of the Traffic in Persons and of the Exploitation of the Prostitution of Others; the sanitary and social registry of prostitutes — created by law on April 24, 1946, and listing about 30,000 people in 1960 — is abolished. July 13, 1965: Law reforming matrimonial regimes: modification of the legal regime for marriages without a contract: the wife is free to manage her own property and pursue professional activity, no longer needing her husband's consent. September 29, 1965: Order establishing a study and liaison committee on women's labor issues. July 11, 1966: Law reforming adoption. December 30, 1966: Law on job protection in cases of maternity.
On 11 August, Lula and ministers unveiled a new Growth Acceleration Programme, according to the proposal, an estimated 1.7 trillion reais (worth around US$350 billion at the time) will be spent over the following 4 years. Of this, 610 billion is expected to be spent on slum urbanisation programmes, including the development of housing, public transport, sanitation, energy and protection from natural disasters, this includes further investments on social infrastructure programmes such as Minha Casa, Minha Vida, Luz Para Todos and Água Para Todos, as well as creation and expansion of ports, airports, motorways and railways. 540 billion is expected to be spent on expanding the electric grid and petrochemical industries, with 80% of the newly developed electric production capacity being expected to come from renewable sources; 349 billion is expected to be spent on transportation infrastructure, including for motor vehicles, trains, marine vehicles, and aeroplanes. Lula also announced the construction of the "West-East Integration Railway (FIOL)" as the first project of the programme, which will connect the southwest of Bahia to the coast of southern Bahia. Other areas of investment include "digital inclusion and connectivity" (expansion of 4G and 5G networks and digital education), healthcare (construction of new basic health units and maternities, as well purchase of ambulances and vaccines), education (construction, expansion and modernization of day care centers, full-time schools and federal institutes and universities) and defence infrastructure.
The nociceptin opioid peptide receptor (NOP), also known as the nociceptin/orphanin FQ (N/OFQ) receptor or kappa-type 3 opioid receptor, is a protein that in humans is encoded by the OPRL1 (opioid receptor-like 1) gene. The nociceptin receptor is a member of the opioid subfamily of G protein-coupled receptors whose natural ligand is the 17 amino acid neuropeptide known as nociceptin (N/OFQ). This receptor is involved in the regulation of numerous brain activities, particularly instinctive and emotional behaviors. Antagonists targeting NOP are under investigation for their role as treatments for depression and Parkinson's disease, whereas NOP agonists have been shown to act as powerful, non-addictive painkillers in non-human primates. Although NOP shares high sequence identity (~60%) with the ‘classical’ opioid receptors μ-OP (MOP), κ-OP (KOP), and δ-OP (DOP), it possesses little or no affinity for opioid peptides or morphine-like compounds. Likewise, classical opioid receptors possess little affinity towards NOP's endogenous ligand nociceptin, which is structurally related to dynorphin A.
Sources: en.wikipedia.org
=== 11 January === Russian Defence Minister Sergei Shoigu appointed Valery Gerasimov in place of Sergey Surovikin as overall commander of the war against Ukraine. Surovikin would serve as Gerasimov's deputy. The Wagner Group claimed around 500 Ukrainians were killed during the battle of Soledar.
=== Wound healing === Low level laser therapy has been studied as a potential treatment for chronic wounds, and higher-power lasers have sometimes been successfully used to close acute wounds as an alternative to stitching. However, as of 2012 and due to inconsistent results and the low quality of extant research, reviews in the scientific literature have not supported its widespread application.
Disordered polymers: In the solid state, atactic polymers, polymers with a high degree of branching and random copolymers form amorphous (i.e. glassy structures). In melt and solution, polymers tend to form a constantly changing "statistical cluster", see freely-jointed-chain model. In the solid state, the respective conformations of the molecules are frozen. Hooking and entanglement of chain molecules lead to a "mechanical bond" between the chains. Intermolecular and intramolecular attractive forces only occur at sites where molecule segments are close enough to each other. The irregular structures of the molecules prevent a narrower arrangement.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.